[1]盛 慧,赵智辉.个性化结直肠癌肿瘤疫苗的制备[J].南京师大学报(自然科学版),2022,45(01):74-80.[doi:10.3969/j.issn.1001-4616.2022.01.011]
　Sheng Hui,Zhao Zhihui.Preparation of Personalized Colorectal Cancer Tumor Vaccine[J].Journal of Nanjing Normal University(Natural Science Edition),2022,45(01):74-80.[doi:10.3969/j.issn.1001-4616.2022.01.011]
点击复制

个性化结直肠癌肿瘤疫苗的制备()
分享到：

《南京师大学报（自然科学版）》[ISSN:1001-4616/CN:32-1239/N]

卷:
第45卷
期数:
2022年01期
页码:
74-80
栏目:
·生物学·
出版日期:
2022-03-15

文章信息/Info

Title:
Preparation of Personalized Colorectal Cancer Tumor Vaccine
文章编号:
1001-4616(2022)01-0074-07
作者:
盛 慧; 赵智辉
(南京师范大学生命科学学院,生物化学与生物制品研究所,江苏省分子与医学生物技术重点实验室,江苏 南京 210023)
Author(s):
Sheng Hui; Zhao Zhihui
(School of Life sciences,Nanjing Normal University,Institute of Biochemistry and Biological Products,
关键词:
结直肠癌; 肿瘤疫苗; 生物正交反应; 树突状细胞
Keywords:
colorectal cancer; tumor vaccine; bioorthogonal reaction; dendritic cells
分类号:
R735.3+7
DOI:
10.3969/j.issn.1001-4616.2022.01.011
文献标志码:
A
摘要:
目前,由于存在肿瘤特异性新抗原难鉴定以及无法将广谱肿瘤抗原通过激活性内吞受体途径递送给抗原提呈细胞等制约因素,使得肿瘤疫苗的临床疗效不佳,同时,肿瘤细胞表面抗原的高度唾液酸化修饰会导致免疫耐受. 所以,本研究尝试利用糖代谢掺入,使肿瘤抗原的唾液酸位点标记上正交基团-叠氮(-N3),同时将特定的激活性吞噬受体的配体标记上另一正交基团-炔烃,通过生物正交反应,制备肿瘤疫苗. 首先,利用分子生物学手段构建了重组质粒,再利用真核系统表达能靶向树突状细胞(dendritic cells,DCs)的重组蛋白mlgG1Fc. 接着,用含正交基团的化合物修饰吞噬受体的配体. 再者,通过代谢掺入途径将叠氮修饰的非天然糖标记到CT26.WT小鼠结直肠癌细胞抗原的糖基化修饰位点,制备N3-TAg. 最后,通过无铜点击反应将吞噬受体的配体与广谱肿瘤抗原缀合,制备个性化结直肠癌肿瘤疫苗. 结果证明,已成功利用真核系统表达出mlgG1Fc蛋白,并获得DIBO修饰的mlgG1Fc蛋白,将mlgG1Fc-DIBO与N3-TAg缀合,制备出个性化且靶向性DCs的结直肠癌肿瘤疫苗. 本研究在理论方法上为制备新型肿瘤疫苗提供了指导意义.
Abstract:
At present,due to the difficulty of identifying tumor-specific antigens and the inability to deliver broad-spectrum tumor antigens to antigen-presenting cells through the activating endocytic receptor pathway,the clinical therapeutic effect of existing tumor vaccines is not good.Meanwhile,the tumor cell antigens with highly sialylated modification can lead to immune tolerance. Therefore,this study tried to use metabolic incorporation to label the sialic acid of the tumor antigen with an orthogonal group-azide(-N3),and at the same time label the ligand of a specific activating phagocytic receptor with another orthogonal group-Alkynes,through bio-orthogonal reactions to prepare tumor vaccines. Firstly,construct and express the recombinant protein mlgG1Fc that can target dendritic cells(DCs),and then modify the ligands of the phagocytic receptor with compounds containing orthogonal groups. Secondly,the azide-modified unnatural sugars are used to label the glycosylation modification sites of CT26.WT colon cancer cell antigen through metabolic incorporation to prepare N3-TAg. Finally,the phagocytic receptor ligand is conjugated with a broad-spectrum tumor antigen through a copper-free click reaction to obtain a colorectal cancer tumor vaccine. The results proved that the use of genetic engineering methods to successfully express the mlgG1Fc protein,and obtain the DIBO-modified mlgG1Fc protein,and conjugate mlgG1Fc-DIBO with N3-TAg to prepare a targeted and stable colorectal cancer tumor vaccine. The research has laid the foundation for the preparation of new tumor vaccines in methodology.

参考文献/References:

[1] CHEN W,SUN K,ZHENG R,et al. Cancer incidence and mortality in China,2014[J]. Chinese journal of cancer research,2018,30(1):1-12.
[2]孙燕,顾晋,汪建平. 中国结直肠癌诊疗规范(2017 年版)[J]. 上海医学,2018,41(8):449-463.
[3]薛婷,冯峰. 结直肠癌能谱CT的研究进展[J]. CT理论与应用研究,2020,29(6):751-758.
[4]ZHANG Y,QIN B L. The research progress of CAR-T cell therapy in the colorectal cancer[J]. Modern oncology,2019,27(1):157-161.
[5]CHEN W,ZHENG R,BAADE P D,et al. Cancer statistics in China,2015[J]. CA:A cancer journal of clinicicans,2016,66(2):115-132.
[6]ZHAO J,CHEN Y,DING Z Y,et al. Safety and efficacy of therapeutic cancer vaccines alone or in combination with immune checkpoint inhibitors in cancer treatment[J]. Front pharmacol,2019,10:1184.
[7]CHRISTOFI T,BARITAKI S,FALZONE L,et al. Current perspectives in cancer immunotherapy[J]. Cancers(basel),2019,11(10):1472.
[8]HE Q,GAO H,WANG J Z. Chinese journal of new drugs[J]. Nature reviews immunology,2020,29(21):2401-2409.
[9]SOLINAS C,AIELLO M,MIGLIORI E,et al. Breast cancer vaccines:heeding the lessons of the past to guide a path forward[J]. Cancer treat rev,2020,84:101947.
[10]HE Q,GAO H,GAO M,et al. Anti-gastrins antiserum combined with lowered dosage cytotoxic drugs to inhibit the growth of human gastric cancer SGC7901 cells in nude mice[J]. Cancer,2015,6(5):448-456.
[11]HE Q,GAO H,GAO M,et al. Immunogenicity and safety of a novel tetanus toxoid-conjugated anti-gastrin vaccine in BALB/c mice[J]. Vaccine,2018,36(6):847-852.
[12]ZHOU Q P. Current status of tumor neoantigen vaccine research[J]. Biological chemical engineering,2020,6(5):154-156.
[13]许若琳,史曼. 树突状细胞与肿瘤免疫[J]. 科学技术创新,2019,35:28-29.
[14]RACHEL L S,SREEKUMAR B,NINA B. Dendritic cell-based immunotherapy[J]. Cell research,2017,27:74-95.
[15]IVAN E,COLOVAI A I. Human Fc receptors:critical targets in the treatment of autoimmune diseases and transplant rejections[J]. Human immunology,2006,67(7):479-491.
[16]祁培培,曹洁. 人免疫球蛋白G Fcγ 受体的细胞分布及其功能研究进展[J]. 细胞与分子免疫学杂志,2012,28(5):557-559.
[17]QIAN J,ZHANG X W,DING J. The effect of sialyltransferases on the sialylated structures in cancer[J]. Chinese bulletin of life sciences,2006,18(3):227-231.
[18]ZHOU X M,YANG G L,GUAN F. Biological functions and analytical strategies of sialic acids in tumor[J]. Cells,2020,9(273):1-17.
[19]陈红梅,张建华,徐仑. KL-6与呼吸系统疾病[J]. 国际儿科学杂志,2008(2):137-139.
[20]LUCHANSKY S J,BERTOZZI C R. Azido sialic acids can modulate cell-surface interactions[J]. Chembiochem:a European journal of chemical biology,2004,5:1706-1709.
[21]KEPPLER O T,HORSTKORTE R,PAWLITA M,et al. Biochemical engineering of the N-acyl side chain of sialic acid:biological implications[J]. Glycobiology,2001,11:11R-18R.
[22]SAXON E,BERTOZZI C R. Cell surface engineering by a modified Staudinger reaction[J]. Science,2000,287:2007-2010.
[23]SONG Y L,ZHU Y Y,ZHOU Y,et al. IFN-γ and tumor immunity[J]. Modern oncology,2021,29(1):0143-0148.
[24]THOMAS S,PRENDERGAST G C. Cancer vaccines:a brief overview[J]. Methods in molecular biology,2016,1403:755-761.
[25]SABADO R L,BALAN S,BHARDWAJ N. Dendritic cell-based immunotherapy[J]. Cell research,2017,27(1):74-95.
[26]黎华丽,郑勇斌. 结直肠癌免疫治疗的研究进展[J]. 山东医药,2019,59(19):90-92.
[27]吴龙龙,宋红丽. 肝脏耐受性树突状细胞与肝移植免疫研究进展[J]. 中华肝胆外科杂志,2021,27(2):149-152.
[28]CHEN J,QIAO Y D,LI X,et al. Intratumoral CD45+CD71+erythroid cells induce immune tolerance and predict tumor recurrence in hepatocellular carcinoma[J]. Cancer letters,2021,499:85-98.
[29]宋政文,赵智辉. 靶向树突状细胞的结肠癌肿瘤疫苗的制备[J]. 南京师大学报(自然科学版),2020,43(3):112-119.

相似文献/References:

[1]张国秀,郑晨晨,赵智辉.特定激活性吞噬受体的配体与广谱肿瘤抗原的化学生物学桥接[J].南京师大学报(自然科学版),2020,43(02):92.[doi:10.3969/j.issn.1001-4616.2020.02.015]
　Zhang Guoxiu,Zheng Chenchen,Zhao Zhihui.Biochemical Bridging of Ligand for Specific Activating PhagocyticReceptor and Broad-Spectrum Tumor Antigens[J].Journal of Nanjing Normal University(Natural Science Edition),2020,43(01):92.[doi:10.3969/j.issn.1001-4616.2020.02.015]
[2]宋政文,赵智辉.靶向树突状细胞的结肠癌肿瘤疫苗的制备[J].南京师大学报(自然科学版),2020,43(03):112.[doi:10.3969/j.issn.1001-4616.2020.03.018]
　Song Zhengwen,Zhao Zhihui.Construction of a Colon Cancer Tumor Vaccine Targeting Dendritic Cells[J].Journal of Nanjing Normal University(Natural Science Edition),2020,43(01):112.[doi:10.3969/j.issn.1001-4616.2020.03.018]
[3]王源源,印学晨,董云菲,等.靶向碱基切除修复途径以克服结直肠癌细胞中的阿霉素耐药性[J].南京师大学报(自然科学版),2023,46(02):61.[doi:10.3969/j.issn.1001-4616.2023.02.008]
　Wang Yuanyuan,Yin Xuechen,Dong Yunfei,et al.Targeting Base Excision Repair Pathway to Overcome Doxorubicin Resistance in Colorectal Cancer Cells[J].Journal of Nanjing Normal University(Natural Science Edition),2023,46(01):61.[doi:10.3969/j.issn.1001-4616.2023.02.008]

备注/Memo

备注/Memo:
收稿日期:2020-12-29.
基金项目:国家自然科学基金面上项目(81273232).
通讯作者:赵智辉,博士,教授,研究方向:肿瘤免疫治疗. E-mail:Zhaozhihui1964_@aliyun.com
更新日期/Last Update: 1900-01-01